HUTCHMED (China) Ltd
HKEX:13
HUTCHMED (China) Ltd
Cost of Revenue
HUTCHMED (China) Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cost of Revenue
-$356.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-26%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cost of Revenue
-HK$4.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-10%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Cost of Revenue
-HK$2.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-15%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Cost of Revenue
-¥7.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cost of Revenue
-¥5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cost of Revenue
-HK$217B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
HUTCHMED (China) Ltd
Glance View
HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.
See Also
What is HUTCHMED (China) Ltd's Cost of Revenue?
Cost of Revenue
-356.3m
USD
Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Cost of Revenue amounts to -356.3m USD.
What is HUTCHMED (China) Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-26%
Over the last year, the Cost of Revenue growth was 7%. The average annual Cost of Revenue growth rates for HUTCHMED (China) Ltd have been -16% over the past three years , -19% over the past five years , and -26% over the past ten years .
You don't have any saved screeners yet